125 stories for 125 years

Colin Reddrop

Dr Colin Reddrop graduated from the college in 1971. After qualifying as a pharmacist, he continued his studies in the USA and the UK (PhD, Brunel, London) in biochemistry and drug disposition in models of liver injury. In 1974 he joined the pharmaceutical industry in Basle, Switzerland, working for the recently merged Ciba-Giegy.

In 1980, Colin joined Astra Pharmaceuticals in Sydney, where he served in a number of executive positions, ultimately leading the medical affairs function in Australia, New Zealand and South-East Asia. He was an active member of the Australian Pharmaceutical Manufacturers Association, the Drug Information Association and was a founding Executive of the Australian Association of Regulatory and Clinical Scientists.

In 1993 Colin was appointed vice-president and Global Head of Regulatory Affairs for Astra AB, based in London. He subsequently served as president of Astra’s first non-Swedish Research and Development (R&D) campus in Loughborough, UK. Since the time of the company merger to AstraZeneca, he has held senior global R&D management positions as vice-president and head, Respiratory and Inflammation Therapy Area and vice-president, Global Drug Development Portfolio and Strategy, both based in the UK and Sweden. He has served on the boards of Astra Pharmaceuticals Ltd (UK), Loughborough University and De Montfort University, Leicester.

Colin has presented keynote addresses at pharmaceutical, regulatory, biopharmaceutical, general management and industry professional conferences around the world. He is currently based in Osaka, Japan, working as senior vice-president, Global Drug Development and head of Japan R&D for AstraZeneca.